- Home
- CRMD vs LBRX Comparison
CRMD vs LBRX Comparison
Compare CRMD & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | LBRX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.2M | 602.6M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRMD | LBRX |
|---|---|---|
| Price | $7.48 | $31.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $14.83 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 959.5K | 299.4K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $311,709,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.71 | ★ N/A |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $6.13 | $13.40 |
| 52 Week High | $17.43 | $33.47 |
Technical Indicators
Market Signals| Indicator | CRMD | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 62.29 |
| Support Level | $7.05 | $21.90 |
| Resistance Level | $8.53 | N/A |
| Average True Range (ATR) | 0.28 | 2.05 |
| MACD | 0.03 | 0.18 |
| Stochastic Oscillator | 46.77 | 71.77 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.